Polynucleotides Injectable Market: Market Size & Forecast 2026

Polynucleotide injectables represent a distinct segment within aesthetic medicine, leveraging purified DNA polymers to activate skin regeneration pathways rather than simply adding volume like traditional fillers. These treatments have found particular favor for delicate applications such as under-eye rejuvenation, where they address fine lines, dark circles, and skin quality through biological stimulation. The global market reached approximately $147 million in 2025 and is experiencing rapid adoption as both practitioners and patients seek regenerative solutions that work with the body's natural healing mechanisms.

• •Primarily used for facial rejuvenation, particularly the under-eye area, as well as for improving overall skin texture and quality
• •Derived from purified salmon DNA fragments and administered via micro-injection or mesotherapy techniques
• •Marketed as a biostimulatory alternative to hyaluronic acid fillers, with effects that develop over weeks as collagen production increases

Robust market expansion stems from multiple reinforcing factors including growing clinical evidence, shifting consumer preferences toward regenerative aesthetics, and increased media visibility. Practitioners are adopting polynucleotides as they seek to differentiate their practices with novel, science-backed treatments that address limitations of conventional fillers. Consumer awareness surged significantly in 2024-2025 following public discussions by celebrities about the treatment, which popularized the 'salmon sperm injection' moniker in mainstream media.

• •Accumulating clinical data demonstrating efficacy in skin rejuvenation, wound healing, and treatment of photoaged skin is building practitioner confidence
• •Celebrity endorsements and extensive social media coverage have accelerated consumer awareness and reduced stigma around polynucleotide treatments
• •Growing preference among aesthetic patients for treatments that enhance the skin's natural regenerative capacity rather than providing temporary volume

Europe commands the largest share of the current market, with Italy serving as a manufacturing and adoption epicenter alongside strong growth in Spain, the United Kingdom, and other Western European nations with mature aesthetic medicine markets. Asia-Pacific is emerging as the fastest-expanding regional segment, particularly in South Korea and Japan, where high aesthetic procedure volumes and biotechnology manufacturing capabilities are fueling local demand. Market segmentation aligns primarily with product formulation types and application areas, with facial rejuvenation representing the dominant use case.

• •Europe leads globally due to early regulatory pathways, established manufacturing infrastructure, and high practitioner familiarity with polynucleotide protocols
• •Asia-Pacific shows the highest regional growth momentum, driven by advanced domestic manufacturing and strong consumer demand for innovative aesthetic treatments
• •Primary application segments include under-eye rejuvenation, facial skin quality improvement, and therapeutic uses for skin repair and scar treatment

What are the recent trends and outlook?

The market trajectory points toward continued expansion as regulatory clarity improves, clinical evidence accumulates, and practitioners refine treatment protocols. Combination therapies, pairing polynucleotides with microneedling, laser treatments, or other aesthetic modalities, are becoming standard practice in advanced clinics seeking synergistic outcomes. The broader consumer shift toward regenerative and preventive aesthetic solutions positions polynucleotides favorably against conventional injectables, suggesting durable long-term demand growth.

• •Combination treatment protocols incorporating polynucleotides with microneedling, laser therapy, or selective fillers are gaining traction as practitioners optimize patient outcomes
• •Ongoing clinical research is exploring expanded applications including hair restoration, scar revision, and treatment of skin damaged by cancer therapies
• •The market's current 15.15% growth rate reflects strong momentum that is expected to sustain as geographic penetration deepens beyond early-adopter regions